30 January 2012

Sareum Holdings plc

("Sareum" or "the Company")

Notice of Results

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business, will announce its Interim Results for the six months ended 31 December 2011 on Monday, 27 February 2012.

Along with its Interim Results, the Company will also provide a research update on its cancer and auto-immune disease drug programmes. 

Enquiries:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / Tim Goodman / Deepak Reddy

020 7947 4350

The Communications Portfolio (Media enquiries)

Ariane Comstive / Caolan Mahon

ariane.comstive@communications-portfolio.co.uk

 

 

020 7536 2028 / 2029

 

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR. For further information, please visit www.sareum.co.uk